Hologic, Inc. (NASDAQ:HOLX – Get Free Report) was the recipient of a large growth in short interest in the month of September. As of September 30th, there was short interest totalling 5,530,000 shares, a growth of 6.8% from the September 15th total of 5,180,000 shares. Approximately 2.4% of the company’s stock are short sold. Based on an average daily trading volume, of 1,530,000 shares, the short-interest ratio is currently 3.6 days.
Hologic Trading Down 1.8 %
Shares of NASDAQ HOLX opened at $80.47 on Friday. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. Hologic has a 12 month low of $64.02 and a 12 month high of $84.67. The company has a market cap of $18.78 billion, a price-to-earnings ratio of 41.06, a P/E/G ratio of 2.89 and a beta of 0.98. The business has a fifty day simple moving average of $80.98 and a 200-day simple moving average of $77.69.
Hologic (NASDAQ:HOLX – Get Free Report) last issued its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, topping the consensus estimate of $1.02 by $0.04. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. Hologic had a return on equity of 19.53% and a net margin of 17.59%. Hologic’s revenue was up 2.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.93 earnings per share. Sell-side analysts predict that Hologic will post 4.09 EPS for the current year.
Insider Buying and Selling
Institutional Trading of Hologic
Institutional investors have recently made changes to their positions in the stock. Innealta Capital LLC bought a new stake in shares of Hologic in the 2nd quarter valued at approximately $25,000. Wolff Wiese Magana LLC acquired a new position in shares of Hologic during the 3rd quarter worth $25,000. iA Global Asset Management Inc. bought a new position in shares of Hologic during the 1st quarter valued at $37,000. Sunbelt Securities Inc. acquired a new stake in shares of Hologic in the 2nd quarter valued at $37,000. Finally, Cranbrook Wealth Management LLC bought a new stake in Hologic in the second quarter worth $47,000. 94.73% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
HOLX has been the topic of several analyst reports. JPMorgan Chase & Co. raised their target price on Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a research report on Tuesday, July 30th. Citigroup lowered shares of Hologic from a “buy” rating to a “neutral” rating and decreased their target price for the company from $95.00 to $85.00 in a research report on Tuesday, October 1st. Evercore ISI boosted their price target on shares of Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. Leerink Partners reduced their price target on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Finally, Mizuho raised their price objective on shares of Hologic from $85.00 to $90.00 and gave the company an “outperform” rating in a research note on Friday, October 4th. Five analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $87.50.
View Our Latest Stock Analysis on HOLX
About Hologic
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Read More
- Five stocks we like better than Hologic
- Stock Market Sectors: What Are They and How Many Are There?
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- How to Calculate Options Profits
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- What Are Trending Stocks? Trending Stocks Explained
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.